norfloxacin has been researched along with Hepatitis C in 2 studies
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.
norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.
Hepatitis C: INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The extensive use of invasive procedures and of long-term norfloxacin prophylaxis in the management of cirrhotic patients may have influenced the epidemiology of bacterial infections in cirrhosis." | 7.71 | Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. ( Arroyo, V; Colmenero, J; Fernández, J; Gómez, J; Navasa, M; Rodés, J; Vila, J, 2002) |
| "Prophylaxis with norfloxacin has been shown to be effective in preventing spontaneous bacterial peritonitis (SBP) in liver cirrhosis." | 3.71 | Spontaneous bacterial peritonitis caused by quinolone-resistant Escherichia coli: could steroid therapy play a role? ( Cereto, F; del Valle Ortiz, O; Esteban, R; Genescà, J; González, A; Guardia, J; Moreno, G; Smithson, A, 2002) |
| "The extensive use of invasive procedures and of long-term norfloxacin prophylaxis in the management of cirrhotic patients may have influenced the epidemiology of bacterial infections in cirrhosis." | 3.71 | Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. ( Arroyo, V; Colmenero, J; Fernández, J; Gómez, J; Navasa, M; Rodés, J; Vila, J, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cereto, F | 1 |
| Genescà, J | 1 |
| Smithson, A | 1 |
| González, A | 1 |
| Moreno, G | 1 |
| del Valle Ortiz, O | 1 |
| Esteban, R | 1 |
| Guardia, J | 1 |
| Fernández, J | 1 |
| Navasa, M | 1 |
| Gómez, J | 1 |
| Colmenero, J | 1 |
| Vila, J | 1 |
| Arroyo, V | 1 |
| Rodés, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Patterns of Antibiotic Resistant Bacterial Infections in Liver Intensive Care Unit[NCT03855709] | 200 participants (Anticipated) | Observational | 2019-05-31 | Not yet recruiting | |||
| Comparison of 3 Days and 7 Days Intravenous Ceftriaxone Prophylaxis in Patients With Acute Variceal Bleeding[NCT00838864] | Phase 4 | 79 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Comparison of Daily Norfloxacin Versus Weekly Ciprofloxacin for the Prevention of Spontaneous Bacterial Peritonitis in Cirrhotic Patients[NCT01542801] | Phase 4 | 124 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| Rifaximin Versus Norfloxacin in the Primary Prophylaxis of Spontaneous Bacterial Peritonitis[NCT04159870] | Phase 3 | 322 participants (Anticipated) | Interventional | 2019-11-05 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 other studies available for norfloxacin and Hepatitis C
| Article | Year |
|---|---|
Spontaneous bacterial peritonitis caused by quinolone-resistant Escherichia coli: could steroid therapy play a role?
Topics: Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Drug Resistance, Bacterial; Escherichia coli; E | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |